Marketing within the European cannabis industry operates under constraints not seen in most sectors. Strict advertising regulations, platform restrictions, limited paid media access, and ongoing stigma create a challenging environment for brand building. At the same time, low brand loyalty and minimal differentiation mean that price and availability often outweigh brand preference.
In this session, Tobias Bosse, CMO of Grünhorn and Managing Director of CanDoc, breaks down how operators are navigating these realities in a rapidly evolving European market. The discussion centres on Germany’s post-legalisation landscape, where demand has surged, competition has intensified, and regulatory uncertainty continues to shape strategy.
Tobias shares practical insights on building sustainable marketing systems without relying on traditional channels, adapting to shifting consumer behaviour, and maintaining credibility in a highly scrutinised industry. The conversation also explores broader market dynamics, from pricing pressure and consolidation to the long-term outlook for cannabis as it moves towards mainstream acceptance.
English Version:
German Version:
Key Highlights and Insights
Market Growth and Demographics
The European cannabis market, particularly following Germany’s partial legalisation in 2024, has seen rapid expansion, with import volumes increasing significantly and competition intensifying. Grünhorn, once holding around 25% market share, now sits closer to 15% as new entrants reshape the landscape. Growth is especially pronounced among the 55+ demographic, driven largely by medical use and improved access rather than recreational demand. Older patients are increasingly turning to cannabis as an alternative to traditional pain treatments such as opioids, with telemedicine playing a critical role in enabling access and normalising usage.
Regulatory Environment and Challenges
While partial legalisation has lowered entry barriers, the regulatory outlook remains uncertain and potentially restrictive. Proposed measures, including mandatory annual physician consultations and possible bans on shipping cannabis products, could significantly disrupt telemedicine-led models. There is a clear need for balanced regulation that supports patient access while maintaining compliance standards. Tobias highlights the importance of introducing certification systems for telemedicine providers, particularly those operating across borders. At the same time, falling product prices following legalisation are placing pressure on margins, raising concerns around long-term product quality and accelerating the likelihood of market consolidation as smaller operators struggle to remain viable.
Marketing and Brand Strategy
Marketing within the cannabis industry remains highly constrained, shaped by strict advertising policies across major platforms. As a result, Grünhorn has prioritised organic growth strategies, particularly SEO, targeting high-intent search terms that drive meaningful conversions. While paid channels are limited, emerging platforms such as Reddit and affiliate networks are proving effective. Tobias cautions against heavy reliance on influencer marketing, particularly high-cost celebrity partnerships, which often lack sustainability and alignment with product value. Instead, the focus is on building trust through subtle, authentic engagement and emotionally resonant branding. Grünhorn’s shift towards a warmer, more approachable visual identity reflects this, moving away from clinical positioning to better connect with patient needs.
Channel Strategy and Consumer Behaviour
Success in cannabis marketing requires a multi-channel approach, as no single platform delivers sufficient impact on its own. Coordinated efforts across channels create the necessary momentum to drive awareness and conversion. In B2B contexts, particularly with pharmacies, the emphasis is less on brand storytelling and more on operational efficiency and e-commerce performance. Consumer behaviour remains highly price-sensitive, with low brand loyalty and a tendency to experiment across products due to the wide range of available options. Initiatives such as sports sponsorships offer a way to build emotional connection and legitimacy, providing consistent content opportunities while helping to position cannabis brands within mainstream culture.
Industry Outlook and Final Thoughts
The German cannabis market continues to mature, with consolidation and increased M&A activity expected as the sector stabilises. Long-term success will depend on striking a balance between regulation and growth, ensuring that compliance does not come at the expense of accessibility or innovation. Tobias underscores the importance of education and transparency in reducing stigma and building trust among both consumers and stakeholders. The industry holds significant economic potential, but its trajectory will be shaped by regulatory decisions and the ability of operators to adapt to an evolving and increasingly competitive environment.
Top Quotes from Nikita and Tobias
"It can never be just one channel, it can never just be one strategy." (When asked about which marketing channel works best)
- Tobias Bosse
"The patient segment that is supposedly growing the most is people over 55 - which is extremely interesting. [There's been] over 640% growth in this segment."
- Nikita Cretu
"Ultimately, I do believe that a good product will always succeed."
- Tobias Bosse
"It was genuinely commercially driven, not just a matter of stigma." (when speaking about why medical cannabis prescriptions have slowly been increasing over the past year)
- Nikita Cretu
"Brand loyalty in this space is virtually non-existent, at least since legalisation."
- Tobias Bosse
"You are slowly heading into fast fashion territory in this space... always cheaper, always lower."
- Nikita Cretu
"We're not trying to do that (typical rapper approach). I think that also dilutes the effect (of marketing) a bit ."
- Tobias Bosse
"It turns out that if you've just spent 7 years at (medical) university and are just graduating, you don't want to be immediately labeled a cannabis doctor."
- Nikita Cretu




